Mayo Clinic helps launch two new companies for improved diagnostics
Related Articles
Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm
Developed in collaboration with Mayo Clinic, with support from Pfizer, this ECG-AI algorithm aims to aid physicians in earlier identification of cardiac amyloidosis{post_date: F d, Y}
Global Electrophysiology Devices Market to Surpass US$ 20,069.2 Million by 2030, Says Coherent Market Insights (CMI)
Coherent Market Insights: The global electrophysiology devices market is expected to exhibit a CAGR of 12.6% during the forecast period due to the increasing organic strategies such as acquisition by…{post_date: F d, Y}
Anumana wins FDA breakthrough nod for AI algorithm that detects pulmonary hypertension
Mass Device: Anumana announced today that it received FDA breakthrough device designation for its pulmonary hypertension (PH) early detection algorithm. Cambridge, Massachusetts-based Anumana, formed by Mayo Clinic and nference and launched in…{post_date: F d, Y}
Charting a Path to the Right Diagnosis with AI Copilots
The rapid growth and widespread adoption of large language models (LLMs) across real-world applications offer a host of new opportunities for the healthcare sector. Hospitals and clinics are starting to…{post_date: F d, Y}